High-dose steroids successfully treated subclinical immune checkpoint inhibitor-associated myocarditis in a 60-year-old male with lung cancer, though ICIs were discontinued due to rising troponin T.
Case Report (n=1)
High-dose steroids can effectively treat subclinical ICI-associated myocarditis, though recurrent troponin elevation may necessitate permanent ICI discontinuation.
BACKGROUND: Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of cancer. Moreover, immune-related adverse events (irAEs) have become a new clinical challenge. ICI-associated myocarditis is a rare but fatal condition among diverse organ injuries, and early recognition and effective interventions are critical for patients. CASE PRESENTATION: In this report, we present the case of a healthy 60-year-old male who was diagnosed with lung squamous cell carcinomas following chemotherapy and received ICIs. The patient presented with asymptomatic cardiac biomarker elevation followed by immune-related myocarditis. Fortunately, the patient achieved a good clinical result after receiving high-dose steroids. The treatment with ICIs was discontinued because of recurrent increases in troponin T. CONCLUSION: ICI-mediated associated myocarditis is an uncommon but potentially life-threatening adverse event. The current data suggest that clinicians need to be cautious about reinitiation in low-grade patients; however, further study of the diagnosis and treatment is necessary.
Hu et al. (Fri,) conducted a case report in Immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer (n=1). Immune checkpoint inhibitors (ICIs) and high-dose steroids was evaluated. High-dose steroids successfully treated subclinical immune checkpoint inhibitor-associated myocarditis in a 60-year-old male with lung cancer, though ICIs were discontinued due to rising troponin T.